Last reviewed · How we verify
generic warfarin #2
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation.
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.
At a glance
| Generic name | generic warfarin #2 |
|---|---|
| Sponsor | Federal University of São Paulo |
| Drug class | Vitamin K antagonist (coumarin anticoagulant) |
| Target | Vitamin K epoxide reductase complex 1 (VKORC1) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin is a coumarin anticoagulant that acts as a vitamin K antagonist. It inhibits the enzyme vitamin K epoxide reductase, which is essential for the carboxylation and activation of vitamin K-dependent clotting factors. This results in decreased synthesis of functional factors II, VII, IX, and X, prolonging the prothrombin time and reducing the risk of thromboembolism.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Mechanical heart valve thromboprophylaxis
- Post-myocardial infarction thromboprophylaxis
Common side effects
- Bleeding (major and minor)
- Warfarin-induced skin necrosis
- Nausea
- Alopecia
- Rash
Key clinical trials
- A Drug Interaction Study of Danicopan (PHASE1)
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- generic warfarin #2 CI brief — competitive landscape report
- generic warfarin #2 updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI